TY - BOOK ID - 146372750 TI - Novel Natural-based Biomolecules Discovery for Tackling Chronic Diseases PY - 2021 PB - Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute DB - UniCat KW - Humanities KW - Social interaction KW - DAPK1 KW - SUMO KW - SENP KW - protein degradation KW - post-translational modification KW - amphibian Bowman-Birk inhibitor KW - Tat peptide KW - molecular cloning KW - antifungal KW - drug design KW - protease inhibitor KW - natural-based compound KW - anticancer therapy KW - lung cancer KW - survivin KW - apoptosis KW - STAT3 KW - colorectal cancer KW - orientin KW - cell cycle arrest KW - Bcl-2 family proteins KW - Astragalus membranaceus KW - insulin KW - PI3K KW - AKT KW - PPARγ KW - PDX-1 KW - Petasites japonicus KW - Asteraceae KW - lignan KW - anti-inflammation KW - NO KW - PGE2 KW - iNOS KW - COX-2 KW - molecular docking KW - peptides KW - kynurenines KW - binding affinity KW - μ-opioid receptor KW - pharmacophore KW - G-protein activation KW - fucoidan KW - PLGA KW - docetaxel KW - drug delivery system KW - anticancer therapy/cancer treatment KW - hIAPP KW - amyloidogenesis KW - insulin granules KW - endoplasmic reticulum KW - anionic lipids KW - F23R variant KW - β-sheet transitions KW - β-cell cytotoxicity KW - unfolded protein response KW - pomegranate KW - punicalagin KW - tannins KW - gingiva KW - fibroblasts KW - antioxidant KW - wound healing KW - branched-chain fatty acids KW - Conidiobolus heterosporus KW - peroxisome proliferator-activated receptor α KW - lipid metabolism KW - fatty acid oxidation KW - hepatocyte KW - DAPK1 KW - SUMO KW - SENP KW - protein degradation KW - post-translational modification KW - amphibian Bowman-Birk inhibitor KW - Tat peptide KW - molecular cloning KW - antifungal KW - drug design KW - protease inhibitor KW - natural-based compound KW - anticancer therapy KW - lung cancer KW - survivin KW - apoptosis KW - STAT3 KW - colorectal cancer KW - orientin KW - cell cycle arrest KW - Bcl-2 family proteins KW - Astragalus membranaceus KW - insulin KW - PI3K KW - AKT KW - PPARγ KW - PDX-1 KW - Petasites japonicus KW - Asteraceae KW - lignan KW - anti-inflammation KW - NO KW - PGE2 KW - iNOS KW - COX-2 KW - molecular docking KW - peptides KW - kynurenines KW - binding affinity KW - μ-opioid receptor KW - pharmacophore KW - G-protein activation KW - fucoidan KW - PLGA KW - docetaxel KW - drug delivery system KW - anticancer therapy/cancer treatment KW - hIAPP KW - amyloidogenesis KW - insulin granules KW - endoplasmic reticulum KW - anionic lipids KW - F23R variant KW - β-sheet transitions KW - β-cell cytotoxicity KW - unfolded protein response KW - pomegranate KW - punicalagin KW - tannins KW - gingiva KW - fibroblasts KW - antioxidant KW - wound healing KW - branched-chain fatty acids KW - Conidiobolus heterosporus KW - peroxisome proliferator-activated receptor α KW - lipid metabolism KW - fatty acid oxidation KW - hepatocyte UR - https://www.unicat.be/uniCat?func=search&query=sysid:146372750 AB - Natural-based biomolecules continuously play an important role in novel drug discovery for the treatment of chronic diseases. The development of natural peptide/protein-based, toxin-based, and antibody-based drugs can significantly improve the biomedical efficiency of disease-specific therapy. The focus of this Special Issue of Biomolecules will be on the most recent advances related to novel peptides/proteins, antibodies, and toxins as forms of medicinal therapy. Recent advances in the discovery and development of these natural biomolecules for use in targeted therapy and immunotherapy against chronic diseases (e.g., cancer, diabetes, cardiovascular diseases, and rheumatoid arthritis) will be addressed. The discussion on using novel disease-specific proteins/peptides/toxins/antibodies along with currently available FDA-approved drugs as combinatorial treatments will also be encouraged in this context. Finally, an overview of some of the selected promising natural biomolecules that are potentially able to address the forthcoming challenges in this field will be included. Both research (in particular) and review articles proposing novelties or overviews, respectively, are welcome. ER -